{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"58.5","upperLimit":"73.8","value":"66.5"},{"groupId":"OG001","lowerLimit":"60.1","upperLimit":"75.1","value":"67.9"}]}],"title":"Accelerated Phase (n=158, 159)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.2","upperLimit":"39.6","value":"28.0"},{"groupId":"OG001","lowerLimit":"18.5","upperLimit":"40.1","value":"28.4"}]}],"title":"Myeloid Blast Phase (n=75,74)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.5","upperLimit":"60.8","value":"42.4"},{"groupId":"OG001","lowerLimit":"15.9","upperLimit":"52.4","value":"32.1"}]}],"title":"Lymphoid Blast Phase (n=33,28)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.7","upperLimit":"54.2","value":"37.5"},{"groupId":"OG001","lowerLimit":"18.6","upperLimit":"47.6","value":"31.8"}]}],"title":"Ph+ Acute Lymphoblastic Leukemia (n=40,44)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"306"},{"groupId":"OG001","value":"305"}],"units":"Participants"}],"description":"MaHR was defined by either complete hematologic response (CHR) or no evidence of leukemia (NEL). CHR defined as: white blood cells (WBC) ≤ upper limit of normal (ULN); absolute neutrophil count (ANC) ≥ 1,000/mm\\^3; platelets ≥ 100,000/mm\\^3; no blasts or promyelocytes in peripheral blood (PB); bone marrow (BM) blasts ≤ 5%; \\<5% myelocytes plus metamyelocytes in PB; basophils in PB \\< 20%; no extra-medullar involvement (including no hepatomegaly or splenomegaly). NEL defined by same criteria as CHR except that platelets and ANC had to satisfy at least one parameter of the following (note that both lower limits had to be satisfied): platelets ≥ 20,000/mm\\^3 and \\< 100,000/mm\\^3; ANC \\> 500/mm\\^3 and \\<1,000/mm\\^3. After Year 2, Amendment 3 allowed participants to switch from the BID to the QD dosing schedule.. Percentage: participants with MaHR/randomized participants.","dispersionType":"95% Confidence Interval","groups":[{"description":"Dasatinib was administered orally at a dose of 140 mg once a day (QD) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant.","id":"OG000","title":"Dasatinib 140 mg QD"},{"description":"Dasatinib was administered orally at a dose of 70 mg twice a day (BID) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant.","id":"OG001","title":"Dasatinib 70 mg BID"}],"paramType":"NUMBER","populationDescription":"Participants were analyzed based on the treatment they were randomized to receive. n=number of participants in disease group.","reportingStatus":"POSTED","timeFrame":"Randomization up to 2 years","title":"Percent of Participants With Major Hematologic Response (MaHR) by Disease Group - Randomized Population","type":"SECONDARY","unitOfMeasure":"percentage of participants"}